CORRECTED: PTAB Nixes Biz Method Review Of Jazz Drug Patents
The Patent Trial and Appeal Board on Tuesday rejected petitions challenging Jazz Pharmaceuticals Inc.'s patents for the narcolepsy drug Xyrem under the America Invents Act business method review program, ruling that...To view the full article, register now.
Already a subscriber? Click here to view full article